# A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

> **NCT03006679** · PHASE3 · WITHDRAWN · sponsor: **Melinta Therapeutics, Inc.**

## Conditions studied

- Hospital-Acquired Bacterial Pneumonia
- Ventilator-Associated Bacterial Pneumonia
- Hospital-Acquired Pneumonia
- Ventilator-Associated Pneumonia

## Interventions

- **DRUG:** Meropenem-Vaborbactam
- **DRUG:** Piperacillin/Tazobactam

## Key facts

- **NCT ID:** NCT03006679
- **Lead sponsor:** Melinta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-08
- **Primary completion:** 2020-06
- **Final completion:** 2020-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2019-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03006679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03006679, "A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03006679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*